NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

LGVN

Longeveron Inc

Jun 30 • 04:00PM ET

1.30

Dollar change -0.02
Percentage change -1.52	%

Healthcare • Biotechnology • USA • NASD

Peers: ADMA CAPR SVRA APRE CVM HOOK JAGX HURA MTNB

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.77	Insider Own	18.58%	Shs Outstand	13.47M	Perf Week	13.04%
Market Cap	19.51M	Forward P/E	-	EPS next Y	-1.17	Insider Trans	-1.00%	Shs Float	12.22M	Perf Month	-0.76%
Enterprise Value	6.47M	PEG	-	EPS next Q	-0.35	Inst Own	7.90%	Short Float	3.11%	Perf Quarter	-17.72%
Income	-25.57M	P/S	8.75	EPS this Y	52.29%	Inst Trans	1.85%	Short Ratio	2.87	Perf Half Y	-26.14%
Sales	2.23M	P/B	1.13	EPS next Y	6.13%	ROA	-110.81%	Short Interest	0.38M	Perf YTD	-24.86%
Book/sh	1.15	P/C	1.36	EPS next 5Y	55.56%	ROE	-167.57%	52W High	6.40 -79.69%	Perf Year	-23.98%
Cash/sh	0.95	P/FCF	-	EPS past 3/5Y	31.57% -11.05%	ROIC	-143.50%	52W Low	1.14 14.04%	Perf 3Y	-97.96%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	22.35% -15.76%	Gross Margin	31.69%	Volatility	7.92% 7.57%	Perf 5Y	-
Dividend TTM	-	EV/Sales	2.90	EPS Y/Y TTM	71.16%	Oper. Margin	-791.51%	ATR (14)	0.10	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.61	Sales Y/Y TTM	127.51%	Profit Margin	-1149.39%	RSI (14)	50.38	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.61	EPS Q/Q	79.24%	SMA20	3.34%	Beta	0.21	Target Price	8.67
Payout	-	Debt/Eq	0.08	Sales Q/Q	-30.47%	SMA50	-5.88%	Rel Volume	0.76	Prev Close	1.32
Employees	26	LT Debt/Eq	0.04	Earnings	May 08 AMC	SMA200	-23.15%	Avg Volume	132.29K	Price	1.30
IPO	Feb 12, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	-3.03% -35.72%	Trades		Volume	100,755	Change	-1.52%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-06-24	Initiated	ROTH MKM	Buy	$10

Jun-26-25 09:05AM	Longeveron Appoints Than Powell as Chief Business Officer (GlobeNewswire)
Jun-24-25 06:30AM	Longeveron Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS) (GlobeNewswire) +7.83%
Jun-09-25 09:15AM	Longeveron to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference (GlobeNewswire)
May-20-25 09:15AM	Longeveron to Attend BIO International Convention 2025 (GlobeNewswire)
May-12-25 07:15AM	Longeveron Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient (GlobeNewswire) +9.70%
04:05PM	Loading…
May-08-25 04:05PM	Longeveron Announces First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) -10.07%
May-02-25 08:30AM	Longeveron to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025 (GlobeNewswire)
Apr-22-25 04:05PM	Longeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Recent Progress and Key Priorities and Goals for 2025 (GlobeNewswire)
Mar-20-25 09:00AM	Longeveron Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer's Disease (GlobeNewswire)
Mar-11-25 08:30AM	Longeveron Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B ) in Alzheimer's Disease (GlobeNewswire) +5.44%
Mar-05-25 09:25AM	Longeveron to Present at the 37th Annual Roth Conference (GlobeNewswire) +5.26%
Feb-28-25 04:04PM	Longeveron Announces Full-Year 2024 Financial Results and Provides Business Update (GlobeNewswire) -9.21%
Feb-21-25 08:30AM	Longeveron to Report Full Year 2024 Financial Results and Host Conference Call on February 28, 2025 (GlobeNewswire)
Feb-19-25 06:00AM	Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now (GlobeNewswire) +5.06%
Feb-18-25 09:25AM	Longeveron Announces World Health Organization Approval of "laromestrocel" as International Non-proprietary Name for Stem Cell Therapy Lomecel-B (GlobeNewswire) -5.39%
09:05AM	Loading…
Feb-14-25 09:05AM	Longeveron to Present at the Emerging Growth Virtual Conference on February 19, 2025 (GlobeNewswire) +6.37%
Dec-18-24 09:10AM	Longeveron to Present at Biotech Showcase 2025 (GlobeNewswire) -7.30%
Dec-07-24 05:20AM	Longeveron initiated with a Buy at Roth MKM (TipRanks)
Dec-04-24 07:00AM	Presenting on the Emerging Growth Conference 77 Day 2 on December 5th Register Now (GlobeNewswire)
Dec-03-24 07:00AM	Presenting on the Emerging Growth Conference 77 Day 1 on December 4th Register Now (GlobeNewswire)
Dec-02-24 09:05AM	Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024 (GlobeNewswire)
Nov-12-24 04:05PM	Longeveron Announces Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) +5.99% -7.83%
Nov-11-24 09:05AM	Longeveron Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC) (GlobeNewswire)
Nov-04-24 04:05PM	Longeveron to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024 (GlobeNewswire) +6.40%
Oct-29-24 10:00AM	Longeveron Presents Lomecel-B Data for Alzheimer's Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) (GlobeNewswire)
Oct-27-24 03:10PM	Longeveron Presents Lomecel-B Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting (GlobeNewswire)
Oct-14-24 09:05AM	Longeveron Lomecel-B Data in Alzheimer's Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) (GlobeNewswire) +8.38%
Oct-09-24 09:05AM	Longeveron Lomecel-B 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting (GlobeNewswire)
Oct-07-24 09:05AM	Longeveron to Present at the UBS Virtual Organ Restoration and Cell Therapy Day (GlobeNewswire)
Oct-02-24 09:05AM	Longeveron to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference (GlobeNewswire)
09:05AM	Loading…
Sep-26-24 09:05AM	Longeveron to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa (GlobeNewswire)
Sep-03-24 09:00AM	Longeveron Announces Positive Type C Meeting with U.S. FDA Regarding Pathway to BLA for Lomecel-B in Hypoplastic Left Heart Syndrome (HLHS) (GlobeNewswire)
Aug-26-24 04:05PM	Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -6.23% -5.39%
Aug-14-24 04:05PM	Longeveron Announces Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -5.75%
Aug-05-24 04:05PM	Longeveron to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024 (GlobeNewswire) -8.30% +9.06%
Jul-28-24 04:51PM	Longeveron Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B in Mild Alzheimer's Disease at the Alzheimer's Association International Conference (AAIC) (GlobeNewswire)
Jul-19-24 04:05PM	Longeveron Announces Closing of $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Jul-18-24 08:45AM	Longeveron Announces $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -16.67%
Jul-17-24 08:00AM	Longeveron Announces U.S. FDA Grants Fast Track Designation for Lomecel-B for the Treatment of Mild Alzheimer's Disease (GlobeNewswire) +10.80%
Jul-10-24 12:08PM	PLUG Stock: Plug Power Shares Hydrogen Refueling Station Update (InvestorPlace) +58.54%
11:34AM	Why Is Longeveron (LGVN) Stock Up 53% Today? (InvestorPlace)
07:30AM	Longeveron Announces U.S. FDA Grants Lomecel-B Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer's Disease (GlobeNewswire)
Jul-09-24 09:00AM	Neha Motwani Elected to Longeveron Board of Directors (GlobeNewswire) +38.65%
Jul-08-24 09:00AM	Gene Therapy Pioneer Roger Hajjar, MD, Elected to Longeveron Board of Directors (GlobeNewswire) +19.65%
Jun-21-24 08:35AM	Life Science Virtual Investor Forum Presentations Now Available for Online Viewing (GlobeNewswire) -10.20%
Jun-19-24 10:30AM	3 Penny Stocks Poised to Turn Pocket Change Into a Small Fortune by 2028 (InvestorPlace)
Jun-18-24 04:48PM	Longeveron Raises $4.4 Million in Gross Proceeds from Warrant Exercise Transaction (GlobeNewswire) -7.50% +10.36%
08:35AM	Life Sciences Virtual Investor Forum Agenda Announced for June 20th (GlobeNewswire)
Jun-17-24 09:45AM	Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase (GlobeNewswire) -24.76%
09:00AM	Longeveron to Present at the Virtual Life Sciences Investor Forum on June 20, 2024 (GlobeNewswire)
08:38AM	Longeveron Announces Exercise of Warrants for $4.4 Million Gross Proceeds (GlobeNewswire)
Jun-12-24 07:00AM	Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now (GlobeNewswire) +120.73%
Jun-11-24 09:00AM	Longeveron Announces Completion of Successful Investigator Meeting for On-going Phase 2b Clinical Trial Evaluating Lomecel-B as a Potential Treatment for HLHS, a Rare Pediatric Cardiac Disease (GlobeNewswire) -22.64%
07:00AM	Presenting on the Emerging Growth Conference 72 Day 1 on June 12 Register Now (GlobeNewswire)
Jun-10-24 09:00AM	Longeveron to Present at the Emerging Growth Virtual Conference on June 12, 2024 (GlobeNewswire)
Jun-03-24 09:00AM	Longeveron Announces Contract Development and Manufacturing Business and First Contract (GlobeNewswire) -5.45%
May-28-24 08:05AM	Longeveron to Attend BIO International Convention 2024 (GlobeNewswire)
May-14-24 04:05PM	Longeveron Announces First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) +6.92%
May-10-24 04:05PM	Longeveron Announces Board of Directors Planned Transitions (GlobeNewswire) -5.52% -10.65%
May-02-24 08:03AM	Longeveron to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024 (GlobeNewswire)
Apr-29-24 09:00AM	Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV (ACCESSWIRE)
Apr-25-24 04:05PM	Longeveron to Present at the Planet MicroCap Showcase (GlobeNewswire)
Apr-19-24 12:13PM	12 Cheap Foods With Anti-Aging Properties That Longevity Scientists Swear By (Insider Monkey)
Apr-18-24 04:05PM	Longeveron Raises a Total of $11.4 Million in Gross Proceeds from Warrant Exercise Offering and Public Offering (GlobeNewswire)
Apr-17-24 08:00AM	Longeveron Announces Exercise of Warrants for $6.2 Million Gross Proceeds (GlobeNewswire) -40.79%
Apr-16-24 01:08PM	Hedge Fund and Insider Trading News: Ken Griffin, Per Johansson, David Tepper, Michael Platt, Third Point LLC, Millennium Management, Bridgewater Associates, Paloma Partners, Longeveron Inc (LGVN), MongoDB, Inc. (MDB) and More (Insider Monkey) +20.48%
Apr-15-24 08:30AM	Longeveron's CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B in Mild Alzheimer's Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer's Association International Conference (AAIC) (GlobeNewswire) +73.37%
08:24AM	Why Is Longeveron (LGVN) Stock Up 48% Today? (InvestorPlace)
Apr-11-24 05:17PM	Longeveron Announces Closing of $5.2 Million Public Offering (GlobeNewswire) -10.22% -16.34%
Apr-08-24 02:15PM	Longeveron Announces Pricing of $5.25 Million Public Offering (GlobeNewswire)
08:30AM	Longeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Clinical Pipeline and 2024 Key Priorities and Goals (GlobeNewswire)
07:56AM	Why Is Longeveron (LGVN) Stock Up 82% Today? (InvestorPlace)
Mar-19-24 04:01PM	Longeveron Announces 1-for-10 Reverse Stock Split (GlobeNewswire) -19.97%
Feb-28-24 10:05AM	With cash runways ending this year, Nicox and Longeveron trim staff and narrow focus (FierceBiotech.com) -5.95%
09:19AM	Longeveron Inc. (NASDAQ:LGVN) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-27-24 04:05PM	Longeveron Reports Year-End 2023 Results and Provides Corporate Update (GlobeNewswire) +7.19%
Feb-21-24 04:05PM	Longeveron to Report Year-End 2023 Results and Provide Corporate Update February 27, 2024 (GlobeNewswire)
Jan-29-24 08:00AM	Longeveron Receives Notice of United States Patent Allowance for the Technology Behind its Lead Investigation Product Lomecel-B (GlobeNewswire) -16.07%
Dec-22-23 04:05PM	Longeveron Announces Closing of $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) +7.20% +8.96%
Dec-21-23 10:34AM	UPDATE -- Longeveron Announces $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -22.84%
08:00AM	Longeveron Announces $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Dec-20-23 08:00AM	Longeveron Announces Additional Positive Clinical Data and Imaging Biomarker Results from the CLEAR MIND Phase 2a Trial of Lomecel-B in the Treatment of Mild Alzheimer's Disease (GlobeNewswire) -16.92%
Nov-14-23 08:17AM	IBN Announces Latest Episode of The Bell2Bell Podcast featuring Wa'el Hashad, CEO of Longeveron Inc. (GlobeNewswire)
Nov-11-23 09:00AM	Long-term Survival Data from Longeveron's ELPIS 1 Trial Presented at the 2023 Scientific Sessions of the American Heart Association (GlobeNewswire)
08:38AM	Longeveron Inc. (NASDAQ:LGVN) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-10-23 07:30AM	Longeveron Reports Third Quarter 2023 Results and Provides Corporate Update (GlobeNewswire) -5.70%
Nov-03-23 08:00AM	Longeveron to Report Third Quarter 2023 Results and Provide Corporate Update on November 10, 2023 (GlobeNewswire)
Oct-24-23 08:30AM	Longeveron Inc. Featured in Syndicated Broadcast Highlighting Top-Line Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B for the Treatment of Mild Alzheimer's (GlobeNewswire)
Oct-13-23 04:05PM	Longeveron Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) +7.43%
Oct-12-23 08:00AM	Longeveron Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -9.24%
Oct-05-23 07:00AM	Longeveron Announces Positive Top-Line Results for Lomecel-B in its CLEAR MIND Phase 2a Clinical Trial in the Treatment of Mild Alzheimer's Disease (GlobeNewswire) -16.73%
Sep-12-23 09:00AM	Longeveron (NASDAQ: LGVN) Reports 100% 5-Year Survival In Trial For Rare Pediatric Disease HLHS (Compared To 80% Survival In Historical Trials) To Market (News Direct)
Sep-11-23 08:00AM	Longeveron Issues Letter to Stockholders (GlobeNewswire)
Sep-07-23 08:30AM	IBN Coverage Initiated for Longeveron Inc. (GlobeNewswire)
08:00AM	Long-term Survival Data from Longeverons ELPIS 1 Trial Accepted for Presentation at the 2023 Scientific Sessions of the American Heart Association (GlobeNewswire)
Sep-05-23 08:00AM	Longeveron to Present at the 25th Annual H.C. Wainwright Global Investment Conference (GlobeNewswire)
07:00AM	Presenting on the Emerging Growth Conference on September 6 and 7 Register Now (GlobeNewswire)
Aug-29-23 08:00AM	Longeveron to Participate in the 149th Annual National Investment Banking Association Conference (GlobeNewswire)
Aug-22-23 08:00AM	Longeveron Rights Offering Subscription Period Begins (GlobeNewswire) +8.20%
Aug-16-23 09:13AM	Longeveron Rights Offering Declared Effective and Calendar Finalized (GlobeNewswire)

Longeveron, Inc. is a clinical stage biotechnology company, which engages in the development of cellular therapies for specific aging-related and life-threatening conditions. Its lead product, LOMECEL-B, is a cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young, healthy, adult donors. The company was founded by Joshua M. Hare and Donald M. Soffer on October 9, 2014 and is headquartered in Miami, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Soffer Rock	Director	May 30 '25	Sale	1.25	11,000	13,750	209,034	Jun 02 06:00 PM
Soffer Rock	Director	May 29 '25	Sale	1.30	10,000	13,000	220,034	Jun 02 06:00 PM
Rock Soffer	Director	May 29 '25	Proposed Sale	1.27	21,000	26,775		May 29 05:34 PM
Soffer Rock	Director	May 22 '25	Sale	1.32	2,000	2,640	230,034	May 27 06:52 PM
Hare Joshua	Chief Scientific Officer	May 16 '25	Sale	1.40	5,250	7,367	721,796	May 16 06:00 PM
Hare Joshua	Officer	May 15 '25	Proposed Sale	1.38	5,250	7,220		May 15 03:20 PM
Baluch Khoso	Director	Dec 02 '24	Sale	2.07	1,250	2,588	23,750	Dec 04 06:00 PM
Baluch Khoso	Director	Nov 27 '24	Proposed Sale	2.06	1,250	2,575		Nov 27 04:43 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LGVN

Longeveron Inc

Upgrade your FINVIZ experience